Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Natco Pharma Limited has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 4 distinct examiners and 4 distinct art units, indicating separate examination paths across the listed portfolio.
STEINKE, SEAN JAMES is the busiest examiner, with 1 pending matter. Counsel should use matter-specific response planning while maintaining consistent treatment of pharmaceutical and biotechnology concepts across the separate assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEINKE, SEAN JAMES | 1 | 12.5% | +42.9% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853465 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ERDAFITINIB | STEINKE, SEAN JAMES | — |
| 18692678 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | MOORE, SUSANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853465 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ERDAFITINIB | STEINKE, SEAN JAMES | — |
| 18692678 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | MOORE, SUSANNA | — |
| 18686927 | AN IMPROVED PROCESS FOR THE PREPARATION OF TRABECTEDIN | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1624 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18853465 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ERDAFITINIB | STEINKE, SEAN JAMES | 1619 | §103§112 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18692678 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | MOORE, SUSANNA | 1624 | §103§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18686927 | AN IMPROVED PROCESS FOR THE PREPARATION OF TRABECTEDIN | CORNET, JEAN P | 1628 | §103 | Final Rejection | — | Pending | Feb 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNatco Pharma Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Sean James Steinke has the most, with 1 of Natco Pharma Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
